2024-10-12 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company that develops and commercializes medicines for a range of life-threatening diseases. 

**Performance Analysis:**

1. **Performance Comparison:**
    - GILD's cumulative return of -11.89% significantly lags behind the S&P 500 (VOO) return of 134.11%. 
    - The relative divergence of -146.0 indicates GILD underperformed the S&P 500 by a substantial margin, positioning it at the 6.09th percentile of historical performance.

2. **Recent Price Action:**
    - Closing price: 85.02
    - 5-day moving average: 85.08
    - 20-day moving average: 84.02
    - 60-day moving average: 78.88
    - The recent price action suggests potential for upward movement, as the stock is trading above its 5, 20, and 60-day moving averages.

3. **Technical Indicators:**
    - RSI: 55.9 -  indicates a neutral trend.
    - PPO: -0.17 - suggests weak price momentum.
    - Delta_Previous_Relative_Divergence: -2.48 - indicates a short-term downward trend.
    - Expected Return: 0.0% - over the next 5 years, GILD is projected to have a 0% return relative to the S&P 500, indicating limited potential for outperformance.

4. **Earnings Performance:**
    - GILD's recent earnings have been volatile, with both positive and negative surprises. The most recent quarter's earnings were $1.29 per share, beating analyst estimates by $0.14. Revenue of $6.95 billion also surpassed expectations.
    - The company's earnings trend is expected to continue to fluctuate, reflecting the cyclical nature of the pharmaceutical industry.

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | $1.29 | $6.95 B |
| 2024-05-08 | -$3.34 | $6.69 B |
| 2023-11-07 | $1.75 | $7.05 B |
| 2023-08-04 | $0.84 | $6.60 B |
| 2024-08-08 | $0.84 | $6.60 B |

5. **News and Recent Issues:**
    - **Market Outlook:** Recent market analysis suggests that GILD's stock price may be influenced by various factors such as ongoing competition in the antiviral market and new drug pipeline developments.
    - **Analyst Opinions:**  Analyst opinions on GILD are mixed. Some analysts remain optimistic about the company's long-term prospects, citing its strong brand recognition, robust drug portfolio, and potential for new product launches. However, others express concerns regarding declining sales of some key products and ongoing legal challenges. 
    - **Performance Highlights:** While GILD has faced challenges in recent years, the company has demonstrated resilience and a commitment to innovation. It continues to invest heavily in research and development, with several new products in its pipeline.

**Summary:**

Gilead Sciences Inc. is a well-established biopharmaceutical company with a strong brand and robust drug portfolio. However, it faces significant challenges in the competitive pharmaceutical market. Recent performance has been mixed, with significant underperformance compared to the S&P 500. While technical indicators suggest potential for upward movement, the expected return remains low, and the company's future performance hinges on its ability to navigate industry challenges and launch new successful products.  
